GILEAD SCIENCES INC shareholders Q2 2024

GILEAD SCIENCES INC's ticker is GILD and the CUSIP is 375558103. A total of 1,634 filers reported holding GILEAD SCIENCES INC in Q2 2024. The put-call ratio across all filers is 0.76 and the average weighting 0.2%.

GILEAD SCIENCES INC shareholders Q2 2024
NameSharesValueWeighting ↓
Sarissa Capital Management LP 1,103,282$75,696,17812.78%
SECTOR GAMMA AS 420,163$28,827,38310.77%
Cutter Capital Management, LP 292,959$20,099,9176.07%
McCarthy Asset Management, Inc. 130,363$8,944,2135.27%
Twin Lakes Capital Management, LLC 76,210$5,228,7523.57%
MORGAN DEMPSEY CAPITAL MANAGEMENT LLC 129,045$8,853,7862.95%
F&V Capital Management, LLC 146,210$10,0312.92%
Sicart Associates LLC 110,130$7,556,0192.90%
Verity & Verity, LLC 357,321$24,515,7692.72%
Virtus Family Office LLC 27,415$1,880,9432.56%
RNC CAPITAL MANAGEMENT LLC 649,418$44,556,5792.47%
CHIRON CAPITAL MANAGEMENT, LLC 37,275$2,557,4592.44%
MILLER HOWARD INVESTMENTS INC /NY 1,068,251$73,292,7142.43%
WALLED LAKE PLANNING & WEALTH MANAGEMENT, LLC 83,702$5,742,7732.34%
Opes Wealth Management LLC 158,751$10,891,9062.27%
CONTINENTAL ADVISORS LLC 75,367$5,170,9302.27%
FOUNDATION RESOURCE MANAGEMENT INC 207,133$14,211,4092.27%
CapWealth Advisors, LLC 257,642$17,676,8142.23%
MEAG MUNICH ERGO, Kapitalanlagegesellschaft mbH 964,066$66,144,5682.20%
Resolute Capital Asset Partners LLC 55,000$3,7742.17%
About GILEAD SCIENCES INC

Gilead Sciences Inc. is a biopharmaceutical company that specializes in the development and commercialization of innovative medicines. The company is headquartered in Foster City, California, and has operations in North America, Europe, and Asia.

Gilead Sciences has a strong portfolio of products that address some of the most pressing medical needs in the world. The company's products are used to treat a range of diseases, including HIV/AIDS, hepatitis B and C, cancer, and respiratory and cardiovascular diseases.

One of the company's most successful products is Truvada, a medication used to prevent the transmission of HIV. Truvada has been a game-changer in the fight against HIV/AIDS, and has helped to significantly reduce the number of new infections in high-risk populations.

Gilead Sciences has also been at the forefront of the fight against COVID-19. The company's antiviral drug, remdesivir, has been approved by the FDA for the treatment of COVID-19 in hospitalized patients. Remdesivir has been shown to reduce the length of hospital stays for COVID-19 patients, and has been hailed as a major breakthrough in the fight against the pandemic.

Overall, Gilead Sciences is a company that is making a real difference in the world of medicine. With a strong portfolio of products and a commitment to innovation, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists GILEAD SCIENCES INC's shareholders in Q2 2024. To view GILEAD SCIENCES INC's shareholder history, click here.